Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stivarga Filings Reinforce Bayer’s HCC Position, For Now

Executive Summary

Bayer has filed Stivarga for use in second-line advanced liver cancer, and is set to dominate this indication in the near future, although serious competition lies in wait.

You may also be interested in...



Liver Cancer: What's Close To The Market

The treatment of liver cancer will have a makeover in coming months, with several products including Bristol’s Opdivo nearing the market for a disease that is often diagnosed late and where previously there have been few meaningful advances in therapy for many years. Two recently published reports from Datamonitor Healthcare have reviewed the disease and the R&D pipeline for the condition.

Rydapt And Alunbrig Approvals Headline Good Week For Targeted Oncologics At US FDA

After almost 20 years, targeted therapy for oncology is still producing breakthroughs. This week saw two breakthrough-designated novel kinase inhibitor approvals, Novartis' Rydapt (midostaurin) and Takeda's Alunbrig (brigatinib), and breakthrough status for Pfizer's next-generation candidate lorlatinib.

Keeping Track: Mylan Submits Biosimilar Herceptin; FDA Clears Opdivo For Head And Neck Cancer

The latest drug development news and highlights from our FDA Performance Tracker.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel